An Early Phase 1 interventional study of HRS-1893 in Hypertrophic Cardiomyopathy, sponsored by Atridia Pty Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Cardiomyopathy, Hypertrophic with a site in Australia — 1 open to participants now, 5 under way, 3 of them phase 3. Cardiomyopathy, Hypertrophic · Australia.
Among the 11 studies in Cardiomyopathy, Hypertrophic with a site in Australia, this one is the only one that started in 2025, is the only one in phase 1, and was the 11th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →1 of the 11 studies in Cardiomyopathy, Hypertrophic with a site in Australia is open now. Recruiting first, the newest first:
Cytokinetics · Sites in Australia, United States, Argentina and 16 more countries
Ages 18–85
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 5 · Phase 4 1
First in 2015; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 162 across the 9 interventional studies, 2,556 across the 2 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Atridia Pty Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Atridia Pty Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 8 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Cardiomyopathy, Hypertrophic with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral low dose of HRS-1893 (dose level 1)
Drug: HRS-1893
Single oral high dose of HRS-1893 (dose level 2)
Drug: HRS-1893
Single dose of HRS-1893 orally administered
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK Cmax: Plasma Cmax
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK AUClast : Plasma AUClast
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK AUC0-inf: Plasma AUC0-inf
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK Tmax :Plasma Tmax
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK t1/2 : Plasma t1/2
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK CL/F: Plasma CL/F
Time frame: Day 8
PK profile of HRS-1893 after a single oral (PO) administration
Pharmacokinetics PK Vz/F: Plasma Vz/F
Time frame: Day 8
Cumulative amount of drug excreted in urine of HRS-1893 after a single oral administration
Cumulative amount of drug excreted in urine (Ae,ur)
Time frame: Day 8
Cumulative percentage of dose recovered in urine of HRS-1893 after a single oral administration:
Cumulative percentage of dose recovered in urine (%Ae,ur)
Time frame: Day 8
Renal clearance of HRS-1893 after a single oral administration
Renal clearance (CLr)
Time frame: Day 8
Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events
Number of participants with Adverse events and Serious adverse events
Time frame: Day 8
Ran from Jun 2025 to primary completion in Sep 2025, 2 months.
Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-1893
Cardiomyopathy, Hypertrophic →